Oncometabolites (Succinate/Fumarate/2-HG) and Epigenetic Crosstalk

Three metabolites, one target family.

One Target Family

Enzyme familyFunctionInhibited by
TET1/2/35mC → 5hmC and further oxidation2-HG (D), succinate, fumarate
KDM2–KDM7 (JmjC)Histone lysine demethylation2-HG, succinate, fumarate
PHD1/2/3 (EGLN)HIF prolyl hydroxylationSuccinate, fumarate, 2-HG at high concentration
FTO, ALKBH5RNA m6A demethylation2-HG, succinate (reported)
Aspartyl/asparaginyl hydroxylasesNotch and other substrates2-HG

Important distinction. These enzymes all use α-ketoglutarate as a co-substrate and Fe(II) as a cofactor, and the oncometabolites act as competitive inhibitors with respect to α-KG. That shared mechanism is why a mutation in SDH, FH or IDH produces similar epigenetic phenotypes, and why the phenotypes are not specific to the mutated gene.

Part 1 — Which Metabolite, Which Consequence

MetaboliteGenetic lesionPrimary epigenetic consequenceSecondary
D-2-HGIDH1/2 neomorphic mutationDNA hypermethylation; blocked differentiationHistone hypermethylation; PHD inhibition at high levels
SuccinateSDHA/B/C/D mutationDNA and histone hypermethylationHIF stabilisation via PHD inhibition
FumarateFH mutationDNA and histone hypermethylationKEAP1 succination → NRF2 activation
L-2-HGL2HGDH loss (rare)Neurological, not typically oncogenic—

Important distinction. D-2-HG and L-2-HG are different molecules with different sources and different clinical associations. The oncogenic one is D-2-HG from mutant IDH. Any measurement that does not resolve the enantiomers is reporting a mixture, and the interpretation is undefined.

Part 2 — Concentration and Compartment

RequirementTypical valueWhy it matters
Intracellular 2-HG in IDH-mutant cellsMillimolarHigh enough to inhibit TET and KDM substantially
Intracellular 2-HG in IDH-wild-type cellsMicromolarFar below the inhibition range
α-KG concentrationMillimolar (mitochondrial), lower cytosolicThe ratio to 2-HG, not the absolute value, sets inhibition
Succinate in SDH-deficient cellsMillimolar (mitochondrial)Cytosolic concentration is lower and less certain
Fumarate in FH-deficient cellsMillimolarSuccination of KEAP1 is detectable at these levels

Caveat on the succinate argument. Succinate accumulates primarily in the mitochondrial matrix, and the cytosolic concentration that reaches nuclear dioxygenases is lower and technically harder to measure. A whole-cell "succinate increased" measurement cannot establish that nuclear TET activity fell; the epigenetic readout, or a nuclear metabolite measurement, is required.

The same caution applies in reverse to fumarate: its effects include succination of cysteine residues, which is a covalent modification rather than competitive inhibition, and the two mechanisms have different dose–response shapes.

Part 3 — The Epigenetic Readouts

ReadoutWhat it reportsMethod
5mC and 5hmCDNA methylation and its oxidised derivativeBisulfite or enzymatic sequencing; LC-MS of hydrolysed DNA
Histone methylation (H3K9me3, H3K27me3, H3K4me3)Demethylase activityImmunoblot, ChIP-seq, mass spectrometry
m6A on RNARNA demethylase activitym6A-seq; LC-MS of nucleosides
Differentiation markersFunctional consequenceExpression and morphology
Global methylation by LC-MSTotal 5mC/5hmC ratioQuantitative, no locus resolution

Readout note. Global 5mC measured by LC-MS is quantitative and cheap, and it reports the aggregate consequence without locus resolution. For a mechanism claim, locus-specific data (sequencing) plus a functional consequence (differentiation block, gene expression) is the stronger package.

Part 4 — Establishing Causality

LevelClaimRequirement
CorrelationMetabolite and methylation change togetherBoth measured in the same cells
DoseThe metabolite causes the changeTitration; or exogenous cell-permeable metabolite
GeneticThe lesion is requiredRe-expression of wild-type enzyme; or mutation reversion
ReversalRemoving the metabolite reverses the markIDH inhibitor with 2-HG and methylation measured
FunctionalThe mark mediates the phenotypeDemethylase perturbation reproducing the phenotype

Caveat on cell-permeable metabolites. Octyl-2-HG and dimethyl-succinate are used to raise intracellular concentrations, and the concentrations required are usually millimolar. Effects at those concentrations may reflect osmotic or metabolic effects rather than specific dioxygenase inhibition; a comparison with a structurally similar but non-inhibitory analogue is the appropriate control.

Part 5 — Model Requirements and Recurring Failures

RequirementWhy
Enantiomer-resolved 2-HGD and L are different
α-KG measured alongsideInhibition depends on the ratio
Compartment consideredWhole-cell averages mitochondrial and cytosolic pools
Wild-type comparatorIsogenic, ideally
Methylation measured quantitativelyGlobal and locus-specific
Functional readoutMethylation alone is a mark

Recurring failures:

  • • Total 2-HG reported without enantiomer resolution.
  • • Whole-cell succinate used to infer nuclear PHD or TET inhibition.
  • • Methylation reported without α-KG, so the ratio is unknown.
  • • Exogenous metabolite effects attributed to specific inhibition, without an analogue control.
  • • A single histone mark reported as "epigenetic reprogramming".
  • • Wild-type and mutant compared across different lines, confounding genotype with background.
  • • IC50 values from recombinant enzymes applied to cells, where concentrations differ.

Part 6 — Where This Article Connects

This is the signalling article of the mitochondrial cluster, and it is where the TCA cycle becomes a chromatin modifier. It connects to the methionine and one-carbon articles, because DNA methylation depends on both the mark's removal (TET) and its maintenance (SAM), and to the respiratory chain article, because the mutations that produce these metabolites are ETC and TCA lesions.

If you need oncometabolite concentrations measured with enantiomer resolution and compartment inference, we can scope the analysis with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Oncometabolite concentrations, compartment distribution and downstream effects vary with genotype, cell type and culture conditions. The values here are ranges from the literature, not thresholds for a specific model.

An epigenetic mark correlated with a metabolite does not establish that the metabolite caused it, and inhibition of a recombinant enzyme does not establish inhibition in the cell.

Scientific interpretation and experimental design

  • • One target family, three metabolites. The phenotypes overlap for a reason.
  • • D and L differ. Resolve them.
  • • The ratio to α-KG sets inhibition, not the absolute value.
  • • Compartment matters for succinate.
  • • Marks are not mechanisms. Add a functional readout.
  • • Analogue controls for permeable metabolites.

Selected references for further reading

  • • Ward PS, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234.
  • • Xiao M, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes & Development. 2012;26:1326–1338.
  • • Sciacovelli M, Frezza C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radical Biology and Medicine. 2016;100:175–181.
  • • Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes & Development. 2013;27:836–852.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: